FDA Approves the First Gene-Editing Treatment for Sickle Cell Disease
The treatment, called Casgevy, is developed by Vertex Pharmaceuticals and CRISPR Therapeutics. It affects approximately 100,000 people in the United States, the majority of whom are Black. The first signs of the disease usually show up within the first year of life. vchal / Getty Images This is a cure. How Does the Treatment Work? The patient must then undergo chemotherapy before the edited stem cells can be inserted back into the patient....